X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs MERCK LTD - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA MERCK LTD CIPLA/
MERCK LTD
 
P/E (TTM) x 44.7 34.7 128.9% View Chart
P/BV x 3.9 3.9 100.5% View Chart
Dividend Yield % 0.3 0.7 45.2%  

Financials

 CIPLA   MERCK LTD
EQUITY SHARE DATA
    CIPLA
Mar-17
MERCK LTD
Dec-16
CIPLA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs6221,060 58.7%   
Low Rs458623 73.6%   
Sales per share (Unadj.) Rs181.9632.4 28.8%  
Earnings per share (Unadj.) Rs12.945.7 28.2%  
Cash flow per share (Unadj.) Rs29.362.3 47.0%  
Dividends per share (Unadj.) Rs2.0011.00 18.2%  
Dividend yield (eoy) %0.41.3 28.3%  
Book value per share (Unadj.) Rs155.7388.8 40.0%  
Shares outstanding (eoy) m804.5116.60 4,846.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.3 223.2%   
Avg P/E ratio x42.018.4 228.0%  
P/CF ratio (eoy) x18.413.5 136.4%  
Price / Book Value ratio x3.52.2 160.3%  
Dividend payout %15.524.1 64.6%   
Avg Mkt Cap Rs m434,51613,969 3,110.6%   
No. of employees `00023.01.6 1,455.7%   
Total wages/salary Rs m26,3381,487 1,771.6%   
Avg. sales/employee Rs Th6,349.16,631.9 95.7%   
Avg. wages/employee Rs Th1,143.0939.2 121.7%   
Avg. net profit/employee Rs Th449.3479.4 93.7%   
INCOME DATA
Net Sales Rs m146,30210,498 1,393.6%  
Other income Rs m2,287242 943.4%   
Total revenues Rs m148,58910,741 1,383.4%   
Gross profit Rs m24,7581,135 2,180.7%  
Depreciation Rs m13,229276 4,801.9%   
Interest Rs m1,5940-   
Profit before tax Rs m12,2221,102 1,108.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,798343 523.6%   
Profit after tax Rs m10,354759 1,364.4%  
Gross profit margin %16.910.8 156.5%  
Effective tax rate %14.731.1 47.2%   
Net profit margin %7.17.2 97.9%  
BALANCE SHEET DATA
Current assets Rs m87,3706,410 1,363.1%   
Current liabilities Rs m33,0818,828 374.7%   
Net working cap to sales %37.1-23.0 -161.1%  
Current ratio x2.60.7 363.8%  
Inventory Days Days8758 150.8%  
Debtors Days Days6238 162.3%  
Net fixed assets Rs m111,5671,406 7,932.8%   
Share capital Rs m1,609166 969.3%   
"Free" reserves Rs m123,6456,286 1,967.0%   
Net worth Rs m125,2546,455 1,940.5%   
Long term debt Rs m36,4540-   
Total assets Rs m209,5328,828 2,373.4%  
Interest coverage x8.7NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.71.2 58.7%   
Return on assets %5.78.6 66.3%  
Return on equity %8.311.8 70.3%  
Return on capital %8.517.1 49.8%  
Exports to sales %34.28.3 413.1%   
Imports to sales %8.321.0 39.6%   
Exports (fob) Rs m50,050869 5,756.8%   
Imports (cif) Rs m12,2032,209 552.4%   
Fx inflow Rs m51,066959 5,326.1%   
Fx outflow Rs m17,6782,612 676.8%   
Net fx Rs m33,388-1,653 -2,019.6%   
CASH FLOW
From Operations Rs m23,8241,070 2,225.7%  
From Investments Rs m-13,127-750 1,750.9%  
From Financial Activity Rs m-13,239-150 8,837.4%  
Net Cashflow Rs m-2,478171 -1,450.0%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 51.8 40.2%  
Indian inst/Mut Fund % 12.2 18.2 67.0%  
FIIs % 23.7 1.0 2,370.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 29.1 90.0%  
Shareholders   161,166 28,591 563.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Crash in Bitcoin, Correction in MidCap and SmallCap Indices and Top Stocks in Action Today(Pre-Open)

The past year has seen the BSE MidCap and BSE SmallCap indices surging by 43.1% and 57.1% respectively. Taking a two year view these indices have produced mind-boggling return of 75.3% .

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 17, 2018 09:11 AM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS